Approach could also be applied to reversing aging and age-related diseases such as hearing loss and macular degeneration
Salk scientists have created a new version of the CRISPR/Cas9 genome editing technology that allows them to activate genes without creating breaks in the DNA, potentially circumventing a major hurdle to using gene editing technologies to treat human diseases.
“Although many studies have demonstrated that CRISPR/Cas9 can be applied as a powerful tool for gene therapy, there are growing concerns regarding unwanted mutations generated by the double-strand breaks through this technology,” says Juan Carlos Izpisua Belmonte, a professor in Salk’s Gene Expression Laboratory and senior author of the new paper, published in Cell on December 7, 2017. “We were able to get around that concern.”
In the original CRISPR/Cas9 system, the enzyme Cas9 is coupled with guide RNAs that target it to the right spot in the genome to create DSBs. Recently, some researchers have started using a “dead” form of Cas9 (dCas9), which can still target specific places in the genome, but no longer cuts DNA. Instead, dCas9 has been coupled with transcriptional activation domains—molecular switches—that turn on targeted genes. But the resulting protein—dCas9 attached to the activator switches—is too large and bulky to fit into the vehicle typically used to deliver these kinds of therapies to cells in living organisms, namely adeno-associated viruses (AAVs). The lack of an efficient delivery system makes it very difficult to use this tool in clinical applications.
Izpisua Belmonte’s team combined Cas9/dCas9 with a range of different activator switches to uncover a combination that worked even when the proteins were not fused to one another. In other words, Cas9 or dCas9 was packaged into one AAV, and the switches and guide RNAs were packaged into another. They also optimized the guide RNAs to make sure all the pieces ended up at the desired place in the genome, and that the targeted gene was strongly activated.
“The components all work together in the organism to influence endogenous genes,” says Hsin-Kai (Ken) Liao, a staff researcher in the Izpisua Belmonte lab and co–first author of the new paper. In this way, the technology operates epigenetically, meaning it influences gene activity without changing the DNA sequence.
To test the method, the researchers used mouse models of acute kidney injury, type 1 diabetes and a form of muscular dystrophy. In each case, they engineered their CRISPR/Cas9 system to boost the expression of an endogenous gene that could potentially reverse disease symptoms. In the case of kidney disease, they activated two genes known to be involved in kidney function, and observed not only increased levels of the proteins associated with those genes, but improved kidney function following an acute injury. For type 1 diabetes, they aimed to boost the activity of genes that could generate insulin-producing cells. Once again, the treatment worked, lowering blood glucose levels in a mouse model of diabetes. For muscular dystrophy, the researchers expressed genes that have been previously shown to reverse disease symptoms, including one particularly large gene that cannot easily be delivered via traditional virus-mediated gene therapies.
“We were very excited when we saw the results in mice,” adds Fumiyuki Hatanaka, a research associate in the lab and co–first author of the paper. “We can induce gene activation and at the same time see physiological changes.”
Izpisua Belmonte’s team is now working to improve the specificity of their system and to apply it to more cell types and organs to treat a wider range of human diseases, as well as to rejuvenate specific organs and to reverse the aging process and age-related conditions such as hearing loss and macular degeneration. More safety tests will be needed before human trials, they say.
The Latest on: CRISPR/Cas9 genome editing technology
- Resistance to Common Germs Poses a Hurdle to New Gene Therapies on January 17, 2018 at 4:41 pm
This prior exposure could potentially render the gene editing ineffective, with the body quickly eliminating all the CRISPR–Cas9 proteins ... “We share everyone’s excitement about doing Cas9 genome editing, but we want to make sure we have learned ... […]
- Human immune response may stymie CRISPR genome editing therapies on January 15, 2018 at 6:25 am
The human adaptive immune response against the Cas9 protein – part of the CRISPR/Cas9 genome editing system – may pose a barrier ... before tests are carried out on humans. 'Like any new technology, you want to identify potential problems and engineer ... […]
- Gene editing could be the future, but doctors think humans might be immune to it on January 12, 2018 at 8:00 pm
Our body's own immune system could present a roadblock to the efforts of medical researchers who aim to develop gene therapies based on the genome-editing tool called CRISPR-Cas9. The genome ... that could render the technology's amazing potential null ... […]
- Human immunity can KILL the CRISPR gene therapy - but the technology is far from dead, expert says on January 8, 2018 at 3:35 pm
The gene-editing technology some thought would change the nature ... Bacteria is still bacteria, to the human body When he and his team tried using the CRISPR Cas9 system to edit the genome in cells from samples of human blood, and reintroduce the ... […]
- New Research Suggests Immunity to CRISPR Gene Editing Poses a Challenge on January 8, 2018 at 10:00 am
CRISPR-Cas9 is the talk of the town in biotechnology. There is a huge amount of public interest in the possibilities provided by this new genome editing technology, and many are hoping CRISPR could eventually cure most genetic disease, with positive impact ... […]
- CRISPR hits a snag: Our immune systems may attack the treatment on January 8, 2018 at 12:00 am
new paper points to a previously unknown hurdle for scientists racing to develop therapies using the revolutionary genome-editing tool CRISPR-Cas9: the human immune ... of the Massachusetts Institute of Technology, who has studied the delivery of CRISPR ... […]
- Bioethicist discusses four keys to know about possibilities, pitfalls of gene editing on January 4, 2018 at 12:51 pm
One of the best known gene editing tools is CRISPR-Cas9, which stands for ... with us and how we use the tool. Technology can be used in many ways: It can be harmful or beneficial. We know so little about the human genome and how it works. […]
- Syngenta obtains non-exclusive IP license from Broad Institute for CRISPR-Cas9 genome-editing technology for agriculture applications on November 1, 2017 at 5:00 pm
Syngenta announced today it has attained a non-exclusive IP license from the Broad Institute of MIT and Harvard for CRISPR-Cas9 genome-editing technology for agricultural applications. CRISPR-Cas9 genome editing technology complements Syngenta’s already ... […]
- CRISPR-Cas9 Editing Can Cause Unexpected Mutations, Researchers Say on May 30, 2017 at 4:18 am
As CRISPR-Cas9 gene editing starts to move into clinical trials, a research team led by scientists at Columbia University Medical Center has found that this technology can introduce hundreds of unintended mutations into the genome. CRISPR-Cas9 editing ... […]
- Editas Medicine Co-founders Present Novel Methods for Improving Genome Editing Specificity in Two Nature Biotechnology Papers on April 25, 2014 at 8:58 am
today announced the publication of new data highlighting novel approaches to improve the specificity of CRISPR/Cas9 genome editing technology. The data are presented in two papers independently co-authored by company co-founders Keith Joung, M.D., Ph.D ... […]
via Google News and Bing News